Low-Molecular-Weight Heparin in Patients with Deep-Vein Thrombosis

To the Editor: The clinical importance of rapidly achieving a therapeutic activated partial-thromboplastin time with respect to the treatment of venous thromboembolism with unfractionated heparin has been underscored in various studies 1 and reviews. 2 Breddin et al. (March 1 issue) 3 compared intra...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 345; no. 4; pp. 292 - 293
Main Authors Stricker, H, Mombelli, G
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 26.07.2001
Subjects
Anticoagulants - administration & dosage
Heparin - administration & dosage
Heparin, Low-Molecular-Weight - administration & dosage
Humans
Partial Thromboplastin Time
Secondary Prevention
Thromboembolism - prevention & control
Thrombosis - drug therapy
Online AccessGet full text

Cover

More Information
Summary:To the Editor: The clinical importance of rapidly achieving a therapeutic activated partial-thromboplastin time with respect to the treatment of venous thromboembolism with unfractionated heparin has been underscored in various studies 1 and reviews. 2 Breddin et al. (March 1 issue) 3 compared intravenous unfractionated heparin with subcutaneous weight-adjusted reviparin, given once or twice a day, as a therapy for deep-vein thrombosis. Reviparin (a low-molecular-weight heparin) was more effective than unfractionated heparin in reducing the size of the thrombus, and twice-daily administration of reviparin prevented recurrent thromboembolism better than did treatment with unfractionated heparin. The patients received fixed initial doses of unfractionated heparin, . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ObjectType-Feature-3
ObjectType-Article-4
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM200107263450413